These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma. Pantuck AJ; Belldegrun AS; Figlin RA N Engl J Med; 2001 Dec; 345(23):1711-2. PubMed ID: 11759660 [No Abstract] [Full Text] [Related]
4. Present achievements in the medical treatment of metastatic renal cell carcinoma. Ravaud A; Debled M Crit Rev Oncol Hematol; 1999 Jun; 31(1):77-87. PubMed ID: 10532192 [No Abstract] [Full Text] [Related]
5. Current clinical practice of induction and maintenance immunotherapy for metastatic renal cell carcinoma. Little B; Young M; Ho KJ Int J Clin Pract; 2002; 56(1):36-9. PubMed ID: 11831831 [TBL] [Abstract][Full Text] [Related]
6. The role of adoptive immunotherapy in solid cancers. Kruit WH; Stoter G Neth J Med; 1997 Feb; 50(2):47-68. PubMed ID: 9050332 [No Abstract] [Full Text] [Related]
7. Complete remission of extensive metastatic renal cancer following immunotherapy. Plowman PN; Costello J; O'Donoghue N Clin Oncol (R Coll Radiol); 1997; 9(3):176-80. PubMed ID: 9269551 [TBL] [Abstract][Full Text] [Related]
9. Removing the primary tumor after the cancer has spread. Tannock IF N Engl J Med; 2001 Dec; 345(23):1699-700. PubMed ID: 11759650 [No Abstract] [Full Text] [Related]
10. Renal cancer immunotherapy: a ray of hope or regression to the mean? Stadler W Cancer Invest; 2000; 18(5):490-1. PubMed ID: 10834033 [No Abstract] [Full Text] [Related]
12. Immunotherapy for renal carcinoma: theoretical basis and current standard of care. Vasey PA Br J Clin Pharmacol; 2000 Dec; 50(6):521-9. PubMed ID: 11136291 [No Abstract] [Full Text] [Related]
13. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma. Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106 [TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for renal cell carcinoma: the era of interleukin-2-based treatment. Taneja SS; Pierce W; Figlin R; Belldegrun A Urology; 1995 Jun; 45(6):911-24. PubMed ID: 7771023 [No Abstract] [Full Text] [Related]
15. [Immunology in clinical practice. XVII. Immunotherapy of metastatic renal cell carcinoma. Work Group Immunotherapy, Dutch Oncology]. van Herpen CM; de Mulder PH Ned Tijdschr Geneeskd; 1998 Nov; 142(48):2613-8. PubMed ID: 10028361 [TBL] [Abstract][Full Text] [Related]
16. Are cytokine responses in renal cell cancer the product of placebo effect of treatment or true biotherapy? What trials are needed now? Oliver RT Br J Cancer; 1998 Apr; 77(8):1318-20. PubMed ID: 9579839 [No Abstract] [Full Text] [Related]
18. Adjuvant treatment with IL-2 or interferon-alpha in renal cell carcinoma: a French multicentric study. Soret JY; Escudier B Cancer Biother Radiopharm; 1996 Oct; 11(5):301-2. PubMed ID: 10851508 [No Abstract] [Full Text] [Related]
19. [Immunotherapy in metastatic cancer of the kidney]. Escudier B Presse Med; 1995 Oct; 24(32):1504-6. PubMed ID: 8545353 [TBL] [Abstract][Full Text] [Related]